Young patients with lung cancer also tend to have a greater number of oncogenic genomic alterations, including ALK and ROS rearrangements and ERBB2 (HER2) alterations (i.e., gene amplification or mutation), suggesting that this population may benefit from targeted therapy [21]. This evidence concerns the gene ALK and lung cancer.